Syros Pharmaceuticals Inc . (NASDAQ:SYRS) stock has reached a new 52-week low, touching down at $0.4. This latest price point marks a significant moment for the company, reflecting a modest 1-year change of 0.37%. Investors are closely monitoring the stock as it navigates through this challenging period, with the 52-week low serving as a critical indicator of the company's current market position. The minimal year-over-year change suggests a relatively stable period for Syros Pharmaceuticals despite the new low, leaving market watchers to speculate on the potential for recovery or further decline.
In other recent news, Syros Pharmaceuticals faced significant developments following its Phase 3 SELECT-MDS-1 trial's failure to meet its primary goal. The trial was testing tamibarotene combined with azacitidine for patients newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS) who exhibit RARA gene overexpression. The trial's results showed a complete response rate of 23.8% in the tamibarotene plus azacitidine group, versus 18.8% in the placebo group—a difference not statistically significant.
This development led to stock downgrades by H.C. Wainwright, TD Cowen, and JMP Securities. H.C. Wainwright downgraded Syros Pharmaceuticals stock to a Neutral rating from Buy, while TD Cowen and JMP Securities downgraded the stock from Buy to Hold and Market Outperform to Market Perform, respectively.
Despite the trial's setback, the safety profile of tamibarotene was consistent with prior studies by Syros, indicating that the drug was generally well tolerated when administered with azacitidine. In light of these events, Syros Pharmaceuticals has stated that it will conduct a thorough analysis of the SELECT-MDS-1 data to decide on future actions for the program.
In financial news, Syros Pharmaceuticals reported no revenue for Q3 2024 and a net loss of $6.4 million. However, the company maintains sufficient cash reserves to fund operations into Q3 2025. Syros is also preparing for the commercial launch of tamibarotene and exploring business development opportunities for the CDK7 inhibitor asset, 5609. These are the recent developments in Syros Pharmaceuticals' journey.
InvestingPro Insights
While Syros Pharmaceuticals Inc. (SYRS) has hit a new 52-week low, recent data from InvestingPro reveals a more nuanced picture of the company's performance. Despite the long-term challenges, SYRS has shown remarkable short-term resilience. InvestingPro data indicates a significant 41.45% return over the last month and an even more impressive 42.19% return over the past three months. These figures suggest a potential turnaround in investor sentiment, which could be crucial for the company's recovery from its current low.
However, it's important to note that SYRS faces substantial financial hurdles. An InvestingPro Tip highlights that the company is "quickly burning through cash," which aligns with the article's mention of the stock's challenging period. Additionally, another InvestingPro Tip points out that SYRS "suffers from weak gross profit margins," further explaining the company's struggle to maintain its market position.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide valuable insights into SYRS's financial health and future prospects. These additional tips could be particularly useful in understanding the complex factors contributing to the company's current market position and its potential for recovery.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.